FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.